Jyong Biotech (MENS) said Thursday that a phase 2 trial of MCS-8 to potentially treat prostate cancer met the efficacy endpoints.
The company said the data showed that two years of treatment with MCS-8 led to a 27.3% reduction in prostate cancer incidence and a 17.1% reduction in high-grade prostate cancer, achieving the primary and secondary endpoints respectively.
The company also said the investigational drug showed good overall tolerability, providing "an important foundation" for potential phase 3 trials.
Shares of Jyong were up more than 3% in recent trading Thursday.
Price: 30.09, Change: +0.92, Percent Change: +3.14
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments